ULTRAGENYX PHARMACEUTICAL INC. 4,444,444 Shares of Common Stock Underwriting AgreementUltragenyx Pharmaceutical Inc. • November 2nd, 2020 • Pharmaceutical preparations • New York
Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”) an aggregate of 4,444,444 shares (the “Underwritten Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 666,666 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.”
ULTRAGENYX PHARMACEUTICAL INC. [—] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • July 7th, 2014 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
ULTRAGENYX PHARMACEUTICAL INC. SALES AGREEMENTSales Agreement • February 21st, 2024 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
OPEN MARKET SALE AGREEMENTSMUltragenyx Pharmaceutical Inc. • May 7th, 2021 • Pharmaceutical preparations • New York
LEASE AGREEMENTLease Agreement • February 12th, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 15th day of December, 2019, between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Tenant”).
FORM OF INDEMNIFICATION AGREEMENTForm of Indemnification Agreement • March 24th, 2014 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of [ ], by and between Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”) and [ ] (“Indemnitee”).
AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation; and MYSTIC RIVER MERGER SUB INC., a Delaware corporation Dated as of October 2, 2017Agreement and Plan of Merger • October 3rd, 2017 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of October 2, 2017, by and among: ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation (“Parent”); MYSTIC RIVER MERGER SUB INC., a Delaware corporation and a direct, wholly-owned subsidiary of Parent (“Purchaser”); and DIMENSION THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date:Stock Option Agreement • February 21st, 2024 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Ultragenyx Pharmaceutical Inc. 2023 Incentive PlanNon-statutory Stock Option Agreement (Directors) This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference. 1.Grant of Stock Option. The Company grants to the Optionee on the date set forth above (the “Date of Grant”) an option (the “Stock Option”) to purchase, on the terms provided herein and in the Plan, up to the number of shares of Stock set forth above (the “Shares”) with an exercise price per Share as set forth above, in each case subject to adjustment pursuant to Section 7(b) of the Plan in respect of transactions occurring after the date hereof. 2.Meaning of Certain Terms. Except as otherwise defined herein, all capitalized terms used herein have the same me
ContractUltragenyx Pharmaceutical Inc. • November 8th, 2013 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES PURCHASABLE HEREUNDER HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR QUALIFICATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
September 13, 2022 Thomas R. Kassberg Re: Amendment No. 2 to Offer Letter Dear Tom:Ultragenyx Pharmaceutical Inc. • November 3rd, 2022 • Pharmaceutical preparations
On behalf of Ultragenyx Pharmaceutical Inc. (the “Company”), I am pleased to present to you this Amendment No. 2 (this “Amendment”), which amends the Offer of Employment Letter Agreement with you dated October 31, 2011 and as amended by Amendment No. 1 dated August 8, 2014 (collectively, the “Offer Letter”) as follows:
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of June 18, 2014 (“Effective Date”) by and between Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13th Floor, Cambridge, MA 02142 (“Dimension”), and Bayer HealthCare LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 455 Mission Bay Blvd South, San Francisco, CA 94158 (“Bayer”). Dimension and Bayer are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
OPTION AND LICENSE AGREEMENTOption and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This OPTION AND LICENSE AGREEMENT (“Agreement”) is entered into as of March 10, 2015 (the “Execution Date”), with effectiveness as of February 18, 2014 (the “Effective Date”), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
INDENTURE OF LEASEIndenture of Lease • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Massachusetts
Agreement entered into this 11thday of March, 2014 in consideration of the covenants and other benefits herein contained the receipt and sufficiency of said consideration being hereby acknowledged.
COLLABORATION AND LICENSE AGREEMENT by and between KYOWA HAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013Collaboration and License Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is made effective as of August 29, 2013 (the “Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“KHK”), and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of California, U.S.A., with an address at 60 Leveroni Ct. Novato, CA 94949, U.S.A. (“UGNX”). KHK and UGNX are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF MAY 5, 2016 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND DIMENSION THERAPEUTICS, INC.License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of May 5, 2016 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
LICENSE AGREEMENTLicense Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (“Agreement”) is entered into as of October 30, 2013 (“Effective Date”) by and between ReGenX Biosciences, LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 750 17thStreet, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13thFloor, Cambridge, MA 02142 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND ULTRAGENYX PHARMACEUTICAL INC. JUNE 6, 2016Confidential Treatment Requested • December 12th, 2016 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of the 6th day of June, 2016 (the “Execution Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”), and Ultragenyx Pharmaceutical Inc., a company incorporated under the laws of California, having its principal place of business at 60 Leveroni Court, Novato, CA 94949, United States (“Ultragenyx”). Ultragenyx and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PERFORMANCE STOCK UNIT AGREEMENT (2020)2014 Incentive Plan • May 7th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences an award (the “Award”) of performance stock units (the “Performance Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
AMENDMENT NO. 1 TO LICENSE AND SERVICES AGREEMENTLicense and Services Agreement • November 8th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO LICENSE AND SERVICES AGREEMENT (herein referred to as “Amendment No. 1”) is made and entered into as of this September 4th, 2012 (the “Amendment No. 1 Effective Date”), by and between Ultragenyx Pharmaceutical, Inc. (herein referred to as “Ultragenyx”), a California Corporation, and The Buck Institute for Research on Aging, an independent non-profit research organization organized under the laws of California (“Buck”), each herein referred to individually as “Party” and collectively as “Parties”.
License AgreementLicense Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
LICENSE AGREEMENTLicense Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
Effective as of September 1, 2012 (the “Effective Date”), St. Jude Children’s Research Hospital, having a principal place of business at (“INSTITUTION”), and Ultragenyx Pharmaceutical, Inc., a Delaware corporation having a principal place of business at 60 Leveroni Court, Novato, CA (“LICENSEE”), agree as follows:
License and Services AgreementLicense and Services Agreement • November 8th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This License and Services Agreement (“Agreement”) is entered into on September 24, 2010 by and between The Buck Institute for Age Research, an independent non-profit research organization (“Buck”) with facilities at 8001 Redwood Blvd., Novato, CA 94945 (“Facility”) and Ultragenyx Pharmaceutical Inc., a California corporation, located at 77 Digital Drive, Suite 210, Novato, CA 94949 (“Ultragenyx”).
Name: Number of Shares of Stock subject to Stock Option: Price Per Share: Date of Grant: Vesting Start Date:Stock Option Agreement • February 21st, 2024 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Ultragenyx Pharmaceutical Inc. 2023 Incentive Planincentive Stock Option Agreement This agreement (this “Agreement”) evidences a stock option granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference. 1.Grant of Stock Option. The Company grants to the Optionee on the date set forth above (the “Date of Grant”) an option (the “Stock Option”) to purchase, on the terms provided herein and in the Plan, up to the number of shares of Stock set forth above (the “Shares”) with an exercise price per Share as set forth above, in each case subject to adjustment pursuant to Section 7(b) of the Plan in respect of transactions occurring after the date hereof. 2.Meaning of Certain Terms. Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 8th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”), dated June 15, 2011, is between ULTRAGENYX PHARMACEUTICAL INC. (the “Company”) and EMIL D. KAKKIS, M.D., PH.D. (“Executive”).
LICENSE AGREEMENTLicense Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Delaware
This License Agreement is entered into as of the 1st day of March, 2011 (the “EFFECTIVE DATE”) between AAIPharma Services Corp., having its principal offices at 2320 Scientific Park Drive, Wilmington, North Carolina 28405 (hereinafter “AAI”), and Ultragenyx Pharmaceutical, Inc., having principal offices at 77 Digital Drive, Suite 210, Novato, California 94949 (hereinafter “ULTRAGENYX”).
Name: Number of Restricted Stock Units subject to Award: Date of Grant:Stock Unit Agreement • February 21st, 2024 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Ultragenyx Pharmaceutical Inc. 2023 Incentive PlanRestricted Stock Unit Agreement (Directors) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference. 1. Grant of Restricted Stock Units. The Company grants to the Grantee on the date set forth above (the “Date of Grant”) an award consisting of the right to receive on the terms provided herein and in the Plan, one share of Stock with respect to each Restricted Stock Unit forming part of the Award, in each case, subject to adjustment pursuant to Section 7(b) of the Plan in respect of transactions occurring after the date hereof. 2. Meaning of Certain Terms. Except as otherwise defined herein, all capita
COLLABORATION AND LICENSE AGREEMENT BETWEEN NOBELPHARMA CO., LTD. AND ULTRAGENYX PHARMACEUTICALS, INCCollaboration and License Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”), effective as of September 30, 2010 (the “Effective Date”), is made by and between Nobelpharma Co., Ltd., a Japanese corporation, having a principal place of business at Kyodo Bldg. (Horidome), 12-10 Nihonbashi-kobunacho, Chuo-Ku, Tokyo, Japan (“NPC”), and Ultragenyx Pharmaceuticals, Inc., a California corporation, having offices at 77 Digital Drive, Suite 210, Novato, CA 94949, U.S.A. (“UPI”) (each a “Party,” together the “Parties”).
PERFORMANCE STOCK UNIT AGREEMENT (NEW EMPLOYEES)Performance Stock Unit Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences an award (the “Award”) of performance stock units (the “Performance Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Missouri
This License Agreement (the “Agreement”) is made and entered into as of November 22, 2010, (the “Effective Date”) by and between Saint Louis University (“SLU”), having an address at 3700 West Pine Mall, Fusz Memorial Hall, Second Floor, Saint Louis, Missouri 63108, and Ultragenyx Pharmaceutical Inc. (“LICENSEE”), having an address at 77 Digital Drive, Suite 210, Novato, California 94949.
Name: Number of Restricted Stock Units subject to Award: Date of Grant: Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan Restricted Stock Unit Agreement (Directors) This agreement (this “Agreement”) evidences an award (the “Award”) of restricted...Plan Restricted Stock Unit Agreement • August 3rd, 2021 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
SUPPLY AGREEMENT between CREMER OLEO GmbH & Co KG, Glockengiesserwall 3, 20095 Hamburg, Germany — hereinafter referred to as Cremer — and Ultragenyx Pharmaceutical Inc, 60 Leveroni Court, Suite 200, Novato, California 94949, United States of America —...Supply Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Whereas, Ultragenyx is a biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market;
RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) (ex-U.S.)Restricted Stock Unit Agreement • May 10th, 2016 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
Commercial Master Service Agreement Between Ultragenyx Pharmaceutical Inc. Novato, CA 94949 USA (Herein known as “UGX”) And BSP Pharmaceuticals S.p.A. via Appia km 65,561 04013 Latina Scalo (LT), Italy (Herein known as “BSP”) Hereinafter referred to...Commercial Master Service Agreement • February 17th, 2023 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Commercial Master Service Agreement (“AGREEMENT”) is made as of the 22ndday of February, 2021 (“EFFECTIVE DATE”), by and between UGX (on behalf of itself and its Affiliates and subsidiaries), and BSP.
AMENDMENT NO. 10 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 7th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 10 to the Collaboration and License Agreement (this “Amendment”) is made and entered into by and between Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin Co., Ltd.), a company organized and existing under the laws of Japan, with an address at 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“KKC”) and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA (“UGNX”).
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASEConfidential Separation Agreement and General Release • November 25th, 2019 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This Confidential Separation Agreement and General Release (this “Agreement”) is hereby entered into by and between Wladimir Hogenhuis, M.D., an individual (the “Employee”), and Ultragenyx Pharmaceutical Inc., on behalf of itself and all of its affiliated entities (collectively, the “Company”).
